Recent Updates
Recently added Catalysts

MAR002

Phase 2

Acromegaly | Small molecule | Endocrine |cbdMD, Inc.|Last Updated: Aug 24, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment72

FDA Designations

No designations recorded

Clinical trial landscape

MAR002 · 1 trial · 1 indication

Phase 2 1
NCT07641179A Study to Evaluate MAR002 for AcromegalyAcromegaly
RECRUITING72 Analytics
PHASE2RECRUITING
A Study to Evaluate MAR002 for Acromegaly
Acromegaly
NCT0764117972
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with TEAEs (treatment-emergent adverse events), SAEs (serious adverse events), and other laboratory endpoints
Baseline to Week 16

To assess the safety and tolerability of multiple subcutaneous (SC) dose administrations of MAR002 in participants with acromegaly

Percent change from baseline in serum insulin-like growth factor 1 (IGF-1) levels as an average of Week 8 and Week 10
Baseline to Week 10

To assess the effect of MAR002 on serum insulin-like growth factor 1 (IGF-1) levels in participants with acromegaly

Secondary Endpoints

Change from baseline in acromegaly symptoms as measured by the Acromegaly Quality of Life (AcroQoL)
Baseline to Week 10
Change from baseline in acromegaly symptoms as measured by Investigator assessment
Baseline to Week 10
Change from baseline in ring size
Baseline to Week 10
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
MAR002 Dose 1EXPERIMENTALSubcutaneous injection
MAR002 Dose 2EXPERIMENTALSubcutaneous injection
MAR002 Dose 3EXPERIMENTALSubcutaneous injection
Matched PlaceboPLACEBO_COMPARATORSubcutaneous Placebo

Interventions

NameTypeDescription
MAR002DRUGSubcutaneous injection
PlaceboDRUGSubcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: 1. Willing to provide written informed consent and comply with study procedures as specified in this protocol and comply with study treatment. 2. Age 18 to 75 years (inclusive) at screening with active acromegaly confirmed by an endocrinologist specialized in the care of pituita...

Countries:United States
Unlock Eligibility Criteria